Is TKNO or TLPH more profitable?

Talphera has a net margin of 0.00% compared to Alpha Teknova's net margin of -38.37%. Alpha Teknova's return on equity of -24.94% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Alpha Teknova -38.37% -24.94% -16.53% Talphera N/A -92.98% -53.22%

Does the media prefer TKNO or TLPH?

In the previous week, Alpha Teknova had 10 more articles in the media than Talphera. MarketBeat recorded 15 mentions for Alpha Teknova and 5 mentions for Talphera. Alpha Teknova's average media sentiment score of 0.62 beat Talphera's score of 0.12 indicating that Alpha Teknova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Teknova 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Talphera 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, QTTB or TLPH?

Q32 Bio has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 4.92 $29.82M $3.00 5.20 Talphera $30K 2,473.90 -$14.29M -$0.31 N/A

Is QTTB or TLPH more profitable?

Q32 Bio's return on equity of 50.17% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Talphera N/A -92.98% -53.22%

Does the media prefer QTTB or TLPH?

In the previous week, Q32 Bio had 5 more articles in the media than Talphera. MarketBeat recorded 10 mentions for Q32 Bio and 5 mentions for Talphera. Q32 Bio's average media sentiment score of 1.15 beat Talphera's score of 0.12 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talphera 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, TLPH or NAGE?

Niagen Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talphera $30K 2,473.90 -$14.29M -$0.31 N/A Niagen Bioscience $129.42M 1.92 $17.38M $0.18 17.33

Does the media favor TLPH or NAGE?

In the previous week, Niagen Bioscience had 19 more articles in the media than Talphera. MarketBeat recorded 24 mentions for Niagen Bioscience and 5 mentions for Talphera. Talphera's average media sentiment score of 0.12 beat Niagen Bioscience's score of -0.01 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Niagen Bioscience 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ARTV or TLPH more profitable?

Artiva Biotherapeutics' return on equity of -83.31% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -83.31% -70.63% Talphera N/A -92.98% -53.22%

Does the media refer more to ARTV or TLPH?

In the previous week, Artiva Biotherapeutics and Artiva Biotherapeutics both had 5 articles in the media. Talphera's average media sentiment score of 0.12 beat Artiva Biotherapeutics' score of -0.57 indicating that Talphera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Talphera 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MGNX or TLPH more profitable?

Talphera has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Talphera's return on equity of -92.98% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -44.79% -147.80% -28.40% Talphera N/A -92.98% -53.22%

Does the media prefer MGNX or TLPH?

In the previous week, Talphera had 1 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Talphera and 4 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.34 beat Talphera's score of 0.12 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Talphera 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Talphera (TLPH) Competitors

$1.43 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.42 -0.01 (-1.05%)

As of 08/7/2026 07:40 PM Eastern

Compare

TLPH vs. TKNO, QTTB, NAGE, ARTV, and MGNX

Should you buy Talphera stock or one of its competitors? MarketBeat compares Talphera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Talphera include Alpha Teknova (TKNO), Q32 Bio (QTTB), Niagen Bioscience (NAGE), Artiva Biotherapeutics (ARTV), and MacroGenics (MGNX).

How does Talphera compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Talphera has a net margin of 0.00% compared to Alpha Teknova's net margin of -38.37%. Alpha Teknova's return on equity of -24.94% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-38.37%	-24.94%	-16.53%
Talphera	N/A	-92.98%	-53.22%

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 13.2% of Alpha Teknova shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Talphera has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	8.55	-$17.26M	-$0.31	N/A
Talphera	$30K	2,473.90	-$14.29M	-$0.31	N/A

In the previous week, Alpha Teknova had 10 more articles in the media than Talphera. MarketBeat recorded 15 mentions for Alpha Teknova and 5 mentions for Talphera. Alpha Teknova's average media sentiment score of 0.62 beat Talphera's score of 0.12 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Teknova	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Teknova presently has a consensus target price of $7.00, indicating a potential upside of 8.36%. Talphera has a consensus target price of $3.00, indicating a potential upside of 109.79%. Given Talphera's stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Alpha Teknova has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Summary

Talphera beats Alpha Teknova on 9 of the 15 factors compared between the two stocks.

How does Talphera compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Q32 Bio has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Q32 Bio's return on equity of 50.17% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Talphera	N/A	-92.98%	-53.22%

Q32 Bio currently has a consensus price target of $30.00, indicating a potential upside of 92.31%. Talphera has a consensus price target of $3.00, indicating a potential upside of 109.79%. Given Talphera's higher probable upside, analysts clearly believe Talphera is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Q32 Bio has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.92	$29.82M	$3.00	5.20
Talphera	$30K	2,473.90	-$14.29M	-$0.31	N/A

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Q32 Bio had 5 more articles in the media than Talphera. MarketBeat recorded 10 mentions for Q32 Bio and 5 mentions for Talphera. Q32 Bio's average media sentiment score of 1.15 beat Talphera's score of 0.12 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Q32 Bio beats Talphera on 11 of the 15 factors compared between the two stocks.

How does Talphera compare to Niagen Bioscience?

Talphera (NASDAQ:TLPH) and Niagen Bioscience (NASDAQ:NAGE) are related small-cap companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

In the previous week, Niagen Bioscience had 19 more articles in the media than Talphera. MarketBeat recorded 24 mentions for Niagen Bioscience and 5 mentions for Talphera. Talphera's average media sentiment score of 0.12 beat Niagen Bioscience's score of -0.01 indicating that Talphera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Niagen Bioscience	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Talphera currently has a consensus target price of $3.00, indicating a potential upside of 109.79%. Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 231.20%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Talphera has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

37.7% of Talphera shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Niagen Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	2,473.90	-$14.29M	-$0.31	N/A
Niagen Bioscience	$129.42M	1.92	$17.38M	$0.18	17.33

Niagen Bioscience has a net margin of 12.39% compared to Talphera's net margin of 0.00%. Niagen Bioscience's return on equity of 17.95% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Niagen Bioscience	12.39%	17.95%	13.17%

Summary

Niagen Bioscience beats Talphera on 14 of the 17 factors compared between the two stocks.

How does Talphera compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

In the previous week, Artiva Biotherapeutics and Artiva Biotherapeutics both had 5 articles in the media. Talphera's average media sentiment score of 0.12 beat Artiva Biotherapeutics' score of -0.57 indicating that Talphera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artiva Biotherapeutics has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, Talphera has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Talphera has lower revenue, but higher earnings than Artiva Biotherapeutics. Talphera is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,114.38	-$83.86M	-$3.30	N/A
Talphera	$30K	2,473.90	-$14.29M	-$0.31	N/A

Artiva Biotherapeutics' return on equity of -83.31% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-83.31%	-70.63%
Talphera	N/A	-92.98%	-53.22%

Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 246.05%. Talphera has a consensus price target of $3.00, indicating a potential upside of 109.79%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Artiva Biotherapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

37.7% of Talphera shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Artiva Biotherapeutics beats Talphera on 8 of the 15 factors compared between the two stocks.

How does Talphera compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Talphera has lower revenue, but higher earnings than MacroGenics. Talphera is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$157.08M	1.63	-$74.62M	-$1.10	N/A
Talphera	$30K	2,473.90	-$14.29M	-$0.31	N/A

MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Talphera has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Talphera has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Talphera's return on equity of -92.98% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Talphera	N/A	-92.98%	-53.22%

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Talphera had 1 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Talphera and 4 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.34 beat Talphera's score of 0.12 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MacroGenics currently has a consensus price target of $5.50, suggesting a potential upside of 36.14%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 109.79%. Given Talphera's higher probable upside, analysts plainly believe Talphera is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

MacroGenics beats Talphera on 9 of the 16 factors compared between the two stocks.

Get Talphera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLPH vs. The Competition

Export

Metric	Talphera	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$74.22M	$11.82B	$7.02B	$13.01B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-4.61	790.97	270.57	25.03
Price / Sales	2,473.90	739.18	599.88	84.35
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	3.86	10.28	11.21	6.43
Net Income	-$14.29M	$2.78B	$3.45B	$348.10M
7 Day Performance	7.52%	2.74%	3.41%	2.68%
1 Month Performance	-2.05%	-0.66%	-0.71%	-0.83%
1 Year Performance	249.21%	192.51%	77.31%	23.97%

Talphera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLPH Talphera	2.3436 of 5 stars	$1.43 flat	$3.00 +109.8%	+249.2%	$74.22M	$30K	N/A	19	Upcoming Earnings Analyst Upgrade
TKNO Alpha Teknova	1.3276 of 5 stars	$5.09 +4.9%	N/A	+52.7%	$260.03M	$40.52M	N/A	240	Earnings Report Analyst Upgrade
QTTB Q32 Bio	4.6704 of 5 stars	$15.71 +3.3%	$30.00 +91.0%	+857.1%	$257.91M	$53.74M	5.91	39	Positive News Earnings Report Analyst Revision Gap Up
NAGE Niagen Bioscience	3.2098 of 5 stars	$3.29 +1.9%	$10.50 +219.1%	-67.9%	$257.25M	$129.42M	15.67	120	Trending News Earnings Report Analyst Revision
ARTV Artiva Biotherapeutics	2.7556 of 5 stars	$10.53 +2.0%	$39.00 +270.4%	+308.3%	$255.08M	$250K	N/A	81	Earnings Report Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLPH) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Talphera (TLPH) Competitors

TLPH vs. TKNO, QTTB, NAGE, ARTV, and MGNX

How does Talphera compare to Alpha Teknova?

Summary

How does Talphera compare to Q32 Bio?

Summary

How does Talphera compare to Niagen Bioscience?

Summary

How does Talphera compare to Artiva Biotherapeutics?

Summary

How does Talphera compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Talphera (TLPH) Competitors

TLPH vs. TKNO, QTTB, NAGE, ARTV, and MGNX

How does Talphera compare to Alpha Teknova?

Is TKNO or TLPH more profitable?

Do institutionals and insiders hold more shares of TKNO or TLPH?

Which has better earnings & valuation, TKNO or TLPH?

Does the media prefer TKNO or TLPH?

Do analysts prefer TKNO or TLPH?

Which has more risk & volatility, TKNO or TLPH?

Summary

How does Talphera compare to Q32 Bio?

Which has more risk and volatility, QTTB or TLPH?

Is QTTB or TLPH more profitable?

Do analysts prefer QTTB or TLPH?

Which has higher valuation & earnings, QTTB or TLPH?

Do institutionals & insiders hold more shares of QTTB or TLPH?

Does the media prefer QTTB or TLPH?

Summary

How does Talphera compare to Niagen Bioscience?

Does the media favor TLPH or NAGE?

Do analysts recommend TLPH or NAGE?

Which has more volatility & risk, TLPH or NAGE?

Do insiders & institutionals believe in TLPH or NAGE?

Which has stronger valuation & earnings, TLPH or NAGE?

Is TLPH or NAGE more profitable?

Summary

How does Talphera compare to Artiva Biotherapeutics?

Does the media refer more to ARTV or TLPH?

Which has more risk & volatility, ARTV or TLPH?

Which has higher earnings & valuation, ARTV or TLPH?

Is ARTV or TLPH more profitable?

Do analysts prefer ARTV or TLPH?

Do institutionals and insiders believe in ARTV or TLPH?

Summary

How does Talphera compare to MacroGenics?

Which has stronger earnings & valuation, MGNX or TLPH?

Which has more volatility and risk, MGNX or TLPH?

Is MGNX or TLPH more profitable?

Do institutionals & insiders have more ownership in MGNX or TLPH?

Does the media prefer MGNX or TLPH?

Do analysts recommend MGNX or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools